Compare FLNG & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNG | VCEL |
|---|---|---|
| Founded | 2006 | 1989 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2019 | 1996 |
| Metric | FLNG | VCEL |
|---|---|---|
| Price | $31.39 | $35.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $23.00 | ★ $57.75 |
| AVG Volume (30 Days) | 464.1K | ★ 644.9K |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.59% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.10 |
| Revenue Next Year | $2.14 | $17.95 |
| P/E Ratio | ★ $19.72 | $111.97 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $21.72 | $28.95 |
| 52 Week High | $31.99 | $45.97 |
| Indicator | FLNG | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 61.22 | 59.16 |
| Support Level | $24.71 | $34.26 |
| Resistance Level | $31.99 | $38.48 |
| Average True Range (ATR) | 0.88 | 1.36 |
| MACD | 0.05 | 0.40 |
| Stochastic Oscillator | 94.41 | 96.56 |
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The company's fleet consists of several LNG carriers on the water, and all of its vessels are of the latest generation equipped with two-stroke propulsion. Its fleet consists of M-type, Electronically Controlled, Gas Injection (MEGI) LNG carriers and Generation X Dual Fuel (X-DF) LNG carriers, offering improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. The company has one reportable segment: vessel operations, which generates revenue from the chartering of vessels to customers.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.